Trial Profile
A Single-Arm Feasibility Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk Intrahepatic Cholangiocarcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 May 2023
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Cholangiocarcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms NEO-GAP
- 05 Oct 2022 Planned primary completion date changed from 30 Sep 2021 to 16 Sep 2023.
- 07 Jun 2022 Primary endpoint (Completion of all preoperative and operative therapy) has been met as per results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology